WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Le... ( SHANGHAI China Feb. 5 Asia/

WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board

Date:2/5/2009

SHANGHAI, China, Feb. 5 /PRNewswire-Asia/ - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced the addition of Stewart Hen and Ning Zhao to the WuXi PharmaTech Board of Directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Ge Li, WuXi's Chairman and Chief Executive Officer, commented, ''We welcome the addition of Stewart Hen and Ning Zhao to the board. Each brings invaluable expertise as we work to anticipate and meet our customers' evolving needs for improving R&D productivity.''

Mr. Hen is a managing director at Warburg Pincus LLC, a leading global private equity firm. He focuses on investments in biotechnology and pharmaceuticals, including pharmaceutical outsourcing. Mr. Hen has more than 17 years of experience in the life sciences industry. Prior to Warburg Pincus, he was a consultant at McKinsey & Company serving the pharmaceutical industry. Previously, he worked at Merck in both research and development and manufacturing. Mr. Hen holds an M.B.A. from the Wharton School of the University of Pennsylvania and an M.S. in chemical engineering from the Massachusetts Institute of Technology.

Dr. Zhao, one of WuXi's co-founders, is currently lead advisor to the company's analytical services operations. She was vice president of WuXi's analytical department from 2004 to 2008 and also established its Bio-Analytical Services, Core Analytical Services, and Analytical Development Services departments. She previously worked for Wyeth as a senior research scientist, for Pharmacopeia as a group
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
2. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
3. WuXi PharmaTech Announces Second Quarter 2008 Results
4. WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
5. Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
6. WuXi PharmaTech 2007 Annual Report Available Online
7. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
8. Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars
9. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
10. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
11. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee

Post Your Comments:

WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Le...( SHANGHAI China Feb. 5 Asia/ - WuX...),Health